NewsRoom Articles - Page 567 of 1390

TuesdaySep 01, 2020 3:00 pm

Delcath Systems Inc. (NASDAQ: DCTH) Starts Presentation at The LD 500

Delcath Systems Inc. (NASDAQ: DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's investigational product, melphalan hydrochloride for injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS), is designed to administer high-dose chemotherapy to the liver while minimizing systemic exposure and associated side effects. In addition to the Phase 3 FOCUS trial, the company has initiated a global Phase 3 clinical trial for intrahepatic cholangiocarcinoma (ICC) called 'The ALIGN Trial'. Delcath is also evaluating other forms of metastatic liver cancers. For more information, visit the company's website at www.delcath.com About…

TuesdaySep 01, 2020 3:00 pm

AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF) Starts Presentation at The LD 500

AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF) is an artificial intelligence, machine-learning company that transforms data into knowledge. AnalytixInsight's financial analytics platform, CapitalCube.com, algorithmically analyzes market price data and regulatory filings to create insightful, actionable narratives and research on approximately 50,000 global companies and North American ETFs, providing high-quality financial research and content for investors, information providers, finance portals and media. AnalytixInsight also designs and implements workforce optimization solutions for large global enterprises. AnalytixInsight holds a 49% interest in MarketWall, a developer of fintech solutions for financial institutions. For more information, visit the company's website at AnalytixInsight.com About The LD 500…

TuesdaySep 01, 2020 3:00 pm

Acer Therapeutics Inc. (NASDAQ: ACER) Starts Presentation at The LD 500

Acer Therapeutics Inc. (NASDAQ: ACER) is a pharmaceutical company focused on the acquisition, development and commercialization of treatments for rare and life-threatening diseases with significant unmet medical needs. Acer's pipeline includes four clinical-stage candidates. Acer's product candidates present a relatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. For more information, visit the company's website at www.acertx.com About The LD 500 The LD 500 is the most ambitious project in LD Micro's 14-year history of leading the micro-cap…

TuesdaySep 01, 2020 2:40 pm

Data443 Risk Mitigation Inc. (OTC: ATDS) Starts Presentation at The LD 500

Data443 Risk Mitigation Inc. (OTC: ATDS) is an industry leader in all things data security, providing software and services to enable secure data across local devices, networks, clouds and databases, both at rest and in flight. Its suite of products and services is highlighted by: ARALOC, a market leading secure, cloud-based platform for the management, protection and distribution of digital content to desktop and mobile devices, which protects an organization's confidential content and intellectual property assets from leakage – malicious or accidental – without impacting collaboration between all stakeholders; ArcMail, a leading provider of simple, secure and cost-effective enterprise data…

TuesdaySep 01, 2020 2:40 pm

Milestone Scientific Inc. (NYSE American: MLSS) Starts Presentation at The LD 500

Milestone Scientific Inc. (NYSE American: MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology(R) is its technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional…

TuesdaySep 01, 2020 2:40 pm

Lantern Pharma Inc. (NASDAQ: LTRN) Starts Presentation at The LD 500

Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. The company leverages advances in machine learning, genomics and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to its pipeline of cancer therapeutics. Lantern's focus is to improve outcomes for patients by leveraging its technology to uncover, rescue and develop abandoned or failed drugs. Its current pipeline of three drugs, with two programs in clinical stages and two in preclinical, focuses on cancers that have unique and…

TuesdaySep 01, 2020 2:40 pm

Dolphin Entertainment Inc. (NASDAQ: DLPN) Starts Presentation at The LD 500

Dolphin Entertainment Inc. (NASDAQ: DLPN) is a leading independent entertainment marketing and premium content production company. Through its subsidiaries, 42West, The Door and Shore Fire Media, Dolphin provides expert strategic marketing and publicity services to many of the top brands, both individual and corporate, in the film, television, music and hospitality industries. In December 2019, all three PR firms were ranked among The Observer's 'Power 50 PR Firms in the United States', an unprecedented achievement. Dolphin's acquisition of Viewpoint Creative adds full-service creative branding and production capabilities to its marketing group. Dolphin's legacy content production business, founded by Emmy-nominated CEO…

TuesdaySep 01, 2020 2:30 pm

PacRoots Cannabis Corp. (CSE: PACR) Seeks to Blaze Path with Genetics-Based Approach Towards Cannabis Cultivation

PacRoots Cannabis employs genetic modification to customize cannabis strains in bid to enhance product potency, quality Company has strategic licensing agreement with Phenome One, a bio-tech firm boasting a database of over 350 unique live cannabis strains Partnership allows PacRoots ability to optimize genetic makeup of its cannabis crop based upon plant’s intended end use Use of genetic modification can also help companies cultivate plants which are better suited towards overall yield enhancement, thereby boosting overall profit margins In the late 1860s, Friar Gregor Mendel, an Augustinian monk and scientist living in a monastery in the depths of the Austrian…

TuesdaySep 01, 2020 2:20 pm

Nanotech Security Corp. (TSX.V: NTS) (OTCQX: NTSFF) Starts Presentation at The LD 500

Nanotech Security Corp. (TSX.V: NTS) (OTCQX: NTSFF) manufactures and markets nano-optic products that have brand protection and enhancement applications across a wide range of markets, including banknotes, tax stamps, secure government documents and the pharmaceutical industry. Its products and services include KolourOptik technology, which uses nano-optics for sophisticated security authentication, and Optical Thin Film technology, which is a form of color-shift technology. With billions of security features in circulation, Nanotech Security Corp.'s products include secure and memorable security labels, stripes, patches and color-shifting films for currency authentication and brand protection. For more information, visit the company's website at www.nanosecurity.ca About…

TuesdaySep 01, 2020 2:20 pm

AzurRx BioPharma Inc. (NASDAQ: AZRX) Starts Presentation at The LD 500

AzurRx BioPharma Inc. (NASDAQ: AZRX) is a biopharmaceutical company specializing in the research and development of non-systemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial and the combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. AzurRx is headquartered in New York with scientific operations based in Langlade, France, and clinical operations in Hayward, California. For more information, visit the company's website at www.azurrx.com About…